A technical note on emerging combination approach involved in the onconanotherapeutics.

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Cancer is a leading global cause of mortality, with conventional treatments often yielding poor outcomes and significant side effects.
• Combination chemotherapy can enhance therapeutic response but faces challenges like toxicity, drug resistance, and unfavorable pharmacokinetics.

Purpose of the Study:

• To review advancements in nanocarrier-based combinatorial drug delivery systems for cancer treatment.
• To highlight personalized combinatorial theranostic medicine as a future approach for managing cancer.

Main Methods:

• Exploratory preclinical and clinical studies.
• Formulation of nanocarrier fabricated combinatorial drugs (NFCDs).
• Review of various nano carrier-based combinatorial drug delivery systems.

Main Results:

• Nanocarrier systems offer improved drug stability, targeted delivery, and reduced systemic toxicity.
• NFCDs demonstrate potential for enhanced therapeutic efficacy and better clinical outcomes in cancer management.
• This approach can lower drug exposure and minimize side effects compared to conventional methods.

Conclusions:

• Nanocarrier-based combinatorial drug delivery systems represent a promising strategy for overcoming limitations of conventional cancer chemotherapy.
• Personalized combinatorial theranostic medicine holds potential as a futuristic and effective anticancer treatment approach.